DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.
Nivolumab plus ipilimumab demonstrates survival benefits in unresectable hepatocellular carcinoma but exceeds US cost-effectiveness thresholds at current pricing, with extended dosing intervals or price reductions needed for economic viability.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07511504 |
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07482059 |
A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma |
RECRUITING | PHASE1/PHASE2 |
| NCT07351513 |
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07305428 |
Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study |
RECRUITING | NA |
| NCT07298538 |
Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer |
ACTIVE_NOT_RECRUITING | |
| NCT07230314 |
Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib |
NOT_YET_RECRUITING | PHASE2 |
| NCT07227012 |
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. |
RECRUITING | PHASE1/PHASE2 |
| NCT07204327 |
Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001) |
ACTIVE_NOT_RECRUITING | |
| NCT07141056 |
The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study |
RECRUITING | |
| NCT07110233 |
Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma |
NOT_YET_RECRUITING | NA |
